Otsuka will pay $700 million to Transcend shareholders at closing, with an additional $525 million in contingent payments tied to future sales milestones
The move comes as drug developers face mounting pressure from faster timelines and increasingly complex manufacturing processes
They stressed that while the drug is clinically proven to support weight and blood sugar control, it must be prescribed only after careful patient evaluation and used under strict medical supervision.
The Macau authorization followed a regulatory review that considered prior decisions by both the US FDA) and the European Medicines Agency
The radiotherapy systems include TrueBeam, TrueBeam STx, VitalBeam, and Edge
The collaboration highlights the rising importance of intranasal delivery in developing non-vaccine approaches to respiratory disease prevention
The global, first-in-human, open-label trial will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TRI-611
The announcement marks Dr. Reddy’s Day?1 entry into the GLP?1 receptor agonists therapy space and readiness to serve patients in India
The trial met its primary endpoint, with the combination therapy demonstrating a “statistically significant and clinically meaningful” improvement in radiographic progression-free survival
This linear, covalently closed, double-stranded DNA offers a rapid, cell-free alternative to traditional plasmid DNA, addressing a critical bottleneck in nucleic acid therapeutics development
Subscribe To Our Newsletter & Stay Updated
